ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 128 filers reported holding ESPERION THERAPEUTICS INC NE in Q3 2023. The put-call ratio across all filers is 0.13 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $30 | -98.1% | 295,200 | 0.0% | 0.00% | – |
| Q2 2023 | $1,567 | +4135.1% | 295,200 | -7.3% | 0.00% | -100.0% |
| Q1 2023 | $37 | +48.0% | 318,500 | +1066.7% | 0.01% | +100.0% |
| Q4 2022 | $25 | -100.0% | 27,300 | -24.8% | 0.00% | -70.0% |
| Q4 2021 | $384,000 | +36.7% | 36,300 | +14.9% | 0.01% | +11.1% |
| Q3 2021 | $281,000 | +71.3% | 31,600 | +89.2% | 0.01% | +80.0% |
| Q2 2021 | $164,000 | +51.9% | 16,700 | +10.6% | 0.01% | -16.7% |
| Q1 2021 | $108,000 | +163.4% | 15,100 | -34.9% | 0.01% | +50.0% |
| Q1 2019 | $41,000 | +412.5% | 23,200 | -87.1% | 0.00% | +300.0% |
| Q4 2018 | $8,000 | -97.8% | 180,500 | -14.4% | 0.00% | -95.7% |
| Q3 2018 | $366,000 | -63.6% | 210,800 | +5.7% | 0.02% | -54.0% |
| Q2 2018 | $1,005,000 | +415.4% | 199,397 | +14.5% | 0.05% | +400.0% |
| Q1 2018 | $195,000 | +323.9% | 174,100 | +187.8% | 0.01% | +233.3% |
| Q1 2017 | $46,000 | – | 60,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 2,679,835 | $69,675,000 | 19.39% |
| Endurant Capital Management LP | 207,293 | $5,390,000 | 1.94% |
| Bellevue Group AG | 5,138,451 | $133,599,000 | 1.53% |
| Rhenman & Partners Asset Management AB | 592,225 | $15,398,000 | 1.26% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 1,562,869 | $40,635,000 | 0.93% |
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 31,434 | $817,000 | 0.62% |
| WASATCH ADVISORS LP | 3,998,010 | $103,949,000 | 0.51% |
| HAMILTON LANE ADVISORS LLC | 46,181 | $1,201,000 | 0.45% |
| Boxer Capital, LLC | 500,000 | $13,000,000 | 0.42% |
| DCF Advisers, LLC | 38,500 | $1,001,000 | 0.41% |